Salmeterol Xinafoate API is a long-acting beta-2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).

This active pharmaceutical ingredient is primarily intended for inhalation dosage forms and provides prolonged bronchodilation.

Salmeterol Xinafoate API works by selectively activating beta-2 adrenergic receptors in the bronchial smooth muscle, leading to sustained airway relaxation and improved airflow over an extended duration.

This long-acting bronchodilatory effect helps maintain airway openness, reduce bronchoconstriction, and support long-term symptom control in patients with asthma and COPD.

Salmeterol Xinafoate API is a fine, crystalline powder with high potency and controlled particle characteristics, which makes this API more suitable for low-dose inhalation formulations requiring precise dose uniformity.

Salmeterol Xinafoate API is primarily used in inhalation dosage forms such as dry powder inhalers (DPIs) and metered-dose inhalers (MDIs). These inhalation formulations are designed to deliver the API directly to the lungs, ensuring rapid action with prolonged bronchodilation.

Salmeterol Xinafoate API is also commonly formulated in fixed-dose combination products with inhaled corticosteroids for long-term management of asthma and COPD.

Gangwal Healthcare supplies Salmeterol Xinafoate API manufactured under stringent quality systems and aligned with relevant pharmacopoeial standards.

The Salmeterol Xinafoate API complies with major pharmacopoeial standards such as IP, USP, EP, and BP, making it suitable for use in regulated inhalation formulations.